Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing, China.
Eur Rev Med Pharmacol Sci. 2017 May;21(9):2098-2102.
The involvement of microRNAs in cancer and their potential as biomarkers of prognosis are becoming increasingly appreciated. The aim of this study was to evaluate the clinical importance and prognostic value of miR-342-3p in hepatocellular carcinoma (HCC).
RT-PCR was used to detect the expression of miR-342-3p. The association with clinicopathologic features was analyzed. Kaplan-Meier survival analysis and Cox proportional hazards analysis were used to compare the overall survival between HCC patients with high miR-342-3p expression and those with low miR-342-3p expression.
We found that miR-342-3p expression was significantly decreased in HCC tissues compared with paired adjacent non-tumor tissues (p < 0.001). MiR-342-3p expression was correlated with histologic grade (p = 0.008) and tumor TNM stage (p = 0.001). Kaplan-Meier survival analysis showed that patients in the high miR-342-3p expression group had better overall survival than those in the low miR-342-3p expression group (p < 0.001). Univariate analysis showed that miR-342-3p (p = 0.001), TNM stage (p = 0.002) and histologic grade (p = 0.006) were associated with poor survival rates. Multivariate analysis confirmed that miR-342-3p expression can be used as an independent predictor for HCC prognosis (p = 0.002).
miR-342-3p may serve as a tumor suppressor during HCC progression, and its low expression may be a potential biomarker for poor prognosis of HCC.
越来越多的人认识到 microRNAs 参与癌症发生及其作为预后生物标志物的潜力。本研究旨在评估 miR-342-3p 在肝细胞癌（HCC）中的临床意义和预后价值。
采用 RT-PCR 检测 miR-342-3p 的表达，分析其与临床病理特征的关系。采用 Kaplan-Meier 生存分析和 Cox 比例风险分析比较 miR-342-3p 高表达和低表达 HCC 患者的总生存率。
我们发现 miR-342-3p 在 HCC 组织中的表达明显低于配对的癌旁非肿瘤组织（p<0.001）。miR-342-3p 的表达与组织学分级（p=0.008）和肿瘤 TNM 分期（p=0.001）相关。Kaplan-Meier 生存分析显示，miR-342-3p 高表达组患者的总生存率明显高于低表达组（p<0.001）。单因素分析显示，miR-342-3p（p=0.001）、TNM 分期（p=0.002）和组织学分级（p=0.006）与生存率降低相关。多因素分析证实 miR-342-3p 表达可作为 HCC 预后的独立预测因子（p=0.002）。
miR-342-3p 可能在 HCC 进展过程中起肿瘤抑制作用，其低表达可能是 HCC 预后不良的潜在生物标志物。
